Pipeline

We employ biologics that are designed to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Our two lead molecules, TTI-621 and TTI-622, are innate immune checkpoint inhibitors targeting CD47.

Target

CD47 – Innate Immune Checkpoint

Candidate

TTI-621

Indication

Heme malignancies

DiscoveryPreclinicalEARLY STAGE DEVELOPMENTLATE STAGE DEVELOPMENT

Candidate

TTI-621

Indication

Solid tumors

DiscoveryPreclinicalEARLY STAGE DEVELOPMENTLATE STAGE DEVELOPMENT

Candidate

TTI-622

Indication

Heme malignancies

DiscoveryPreclinicalEARLY STAGE DEVELOPMENTLATE STAGE DEVELOPMENT

Candidate

TTI-622

Indication

Solid tumors

DiscoveryPreclinicalEARLY STAGE DEVELOPMENTLATE STAGE DEVELOPMENT